Ustekinumab Drug Asset Due Diligence Report 2026

This Ustekinumab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

205

Registered trials

499

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Ustekinumab can convert its Monoclonal antibody profile and IL-12p40 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Ustekinumab (query alias: ustekinumab)
Modality / target	Monoclonal antibody; IL-12p40; IL-12p40 inhibitors
Highest global status	Approved
Originator	Janssen Biotech, Inc.
Active developers	Janssen-Cilag International NV, Janssen Research & Development LLC, Janssen-Cilag Pty Ltd.

The MCP disease footprint includes Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07582991	Phase 2	Completed	8	Patients achieving complete remission, marked improvement, and improvement
NCT07694674	Not Applicable	Recruiting	198	Endoscopic recurrence rate
NCT07697547	Not Applicable	Completed	84	Clinical remission rate at Week 12 to Week 16

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn’s Disease: Results of the REScUE Study

Phase 3; n=108; evaluation: Negative. Reported fields: clinical remission(Steroid-free, week 48) = 19.0 % ; clinical remission(Steroid-free, week 48) = 15.0 %

EFFICACY AND SAFETY OF SUBCUTANEOUS USTEKINUMAB IN PEDIATRIC PARTICIPANTS WITH ACTIVE JUVENILE PSORIATIC ARTHRITIS: RESULTS OF THE OPEN-LABEL, PHASE 3 PSUMMIT-JR STUDY THROUGH WEEK 52

Phase 3; n=18; evaluation: Positive. Reported fields: JIA-ACR 30 response(24-week) = 88.9 %

NON-STANDARD TREATMENTS USE IN GIANT CELL ARTERITIS: DATA FROM THE LARGE VESSEL VASCULITIS FRENCH STUDY GROUP

Not Applicable; n=47; evaluation: Positive. Reported fields: AE(discontinuation) = infectious colitis on secukinumab, diverticular-associated pancolitis, severe neutropenia on sarilumab, and interstitial lung disease on tofacitinib. % ; AE(discontinuation) = 19.6 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Ustekinumab addresses Colitis, Ulcerative, Crohn Disease, Arthritis, Psoriatic. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Monoclonal antibody—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2025-09-16	Mitsubishi Tanabe Pharma Corporation will conclude co-promotion activities for the human anti-human IL-12/23p40 monoclonal antibody formulation "Stelara® "	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Class crowding and differentiation versus other PD-(L)1/VEGF agents
Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
Biomarker strategy, indication selection, and head-to-head endpoint execution

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO